Publications

1 2 3 4 5 6 7 12 23 33 44

Raquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M Borras, Jannes Govaerts, Stefan Naulaerts, Zwi N Berneman, Benoit Beuselinck, Kalijn F Bol, Jannie Borst, An Coosemans, Angeliki Datsi, Jitka Fučíková, Lisa Kinget, Bart Neyns, Gerty Schreibelt, Evelien Smits, Rüdiger V Sorg, Radek Spisek, Kris Thielemans, Sandra Tuyaerts, Steven De Vleeschouwer, I Jolanda M de Vries, Yanling Xiao, Abhishek D Garg

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Oncoimmunology. 2022 Jul 4;11(1):2096363. doi: 10.1080/2162402X.2022.2096363. eCollection 2022.

Nicholas J Vogelzang, Tomasz M Beer, Winald Gerritsen, Stéphane Oudard, Pawel Wiechno, Bozena Kukielka-Budny, Vladimir Samal , Jaroslav Hajek, Susan Feyerabend, Vincent Khoo, Arnulf Stenzl, Tibor Csöszi, Zoran Filipovic, Frederico Goncalves, Alexander Prokhorov, Eric Cheung , Arif Hussain, Nuno Sousa, Amit Bahl, Syed Hussain, Harald Fricke, Pavla Kadlecova, Tomas Scheiner, Roman P Korolkiewicz, Jirina Bartunkova, Radek Spisek; VIABLE Investigators

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial

JAMA Oncol. 2022 Apr 1;8(4):546-552. doi: 10.1001/jamaoncol.2021.7298.

Jitka Fucikova, Lenka Palova-Jelinkova, Vanessa Klapp, Peter Holicek, Tereza Lanickova, Lenka Kasikova, Jana Drozenova, David Cibula, Beatriz Álvarez-Abril, Elena García-Martínez, Radek Spisek, Lorenzo Galluzzi.

Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

Trends Cancer. 2022 Feb 15;S2405-8033(22)00017-6. doi: 10.1016/j.trecan.2022.01.010.